Coherus Oncology(NASDAQ) CHRS

Current Price$1.43

Market Cap$220.58M

Since IPO (2014)-89%

5 Year-89%

1 Year+46%

1 Month-2%

Coherus Oncology last closing stock price
Metric	Price	Date
Last close	USD 1.43	2026-07-23

Coherus Oncology stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.88%	USD 1.39	2026-07-16
1 month	-2.05%	USD 1.46	2026-06-23
3 month	-18.29%	USD 1.75	2026-04-24
Year to date	+0.7%	USD 1.42	2025-12-31
1 year	+46.13%	USD 0.98	2025-07-23
3 year	-67.5%	USD 4.40	2023-07-24
5 year	-89.06%	USD 13.07	2021-07-23
Since inception	-88.66%	USD 12.61	2014-11-06

Coherus Oncology Financials at a Glance

Market Cap

$220.58M

Revenue (TTM)

$46.88M

Net Income (TTM)

-$151.66M

EPS (TTM)

-$1.25

P/E Ratio

-1.15

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$1.43

Volume

19,968

Open

$1.43

Price

$1.43

Volume

19,968

Open

$1.43

Previous Close

$1.43

Daily Range

$1.40 - $1.45

52-Week Range

$0.81 - $2.62

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$1.43

Volume

19,968

Open

$1.43

Previous Close

$1.43

Daily Range

$1.40 - $1.45

52-Week Range

$0.81 - $2.62

Estimated Earnings Date

Aug 6, 2026

CHRS News

Page 1

CHRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coherus Oncology

Coherus helps doctors treat cancer by making medicines that strengthen the body's natural defenses. These treatments target tumors in the head, neck, and other organs. The company is moving away from copies of old drugs to focus on new cancer discoveries.

A Targeted Cancer Portfolio

LOQTORZI: An approved antibody that helps the immune system find and kill tumor cells in the head and neck; accounted for $11.8 million of net revenue in Q1 2026.
Casdozokitug: An experimental antibody that blocks a specific protein called Interleukin 27 which helps some cancers grow.
Tagmokitug: A candidate medicine designed to remove specific cells that stop the immune system from attacking solid tumors.

New Partners and Strategic Moves

Sold the biosimilar business to Intas Pharmaceuticals in April 2025 to focus resources on oncology products.
Acquired Surface Oncology to add new experimental drugs for liver and lung cancers to its development pipeline.
Partnered with Junshi Biosciences to co-develop and sell the cancer drug LOQTORZI in the United States and Canada.
Entered an agreement with Janssen in February 2026 to test new combination treatments for prostate cancer.

What Sets Coherus Apart

The company changed its name to Coherus Oncology in May 2025 to reflect its full transition into a specialized cancer research firm. It maintains global rights for its mid-stage drug candidates, which allows it to pursue licensing deals with international partners outside of the United States.

Tracking the Financial Progress

Net revenue reached $12.3 million in Q1 2026, up 62% from Q1 2025.
Gross profit rose to $7.6 million in Q1 2026, up 95.3% year-over-year.
Operating loss narrowed to $36.2 million in Q1 2026, an improvement of 20.4% from the previous year.
Total cash, cash equivalents, and marketable securities were $167 million as of March 31, 2026.

Bottom Line

Coherus has transformed from a maker of biosimilars into a focused biotechnology company developing its own cancer treatments. Its evolution relies on selling off legacy business units to fund a pipeline of new antibodies that target the immune system.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

147

CEO

Denny M. Lanfear, MBA

Website

www.coherus.com

Headquarters

Redwood City, CA 94065, US

CHRS Financials

Key Financial Metrics (TTM)

Gross Margin

60.04%

Operating Margin

-362.07%

Net Income Margin

-323.49%

Return on Equity

-174.71%

Return on Capital

-177.14%

Return on Assets

-57.01%

Earnings Yield

-86.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$220.58M

Shares Outstanding

154.25M

Volume

19.97K

Avg. Volume

1.07M

Financials (TTM)

Gross Profit

$28.15M

Operating Income

-$169.75M

EBITDA

-$159.87M

Operating Cash Flow

-$170.57M

Capital Expenditure

$0.00

Free Cash Flow

-$170.57M

Cash & ST Invst.

$167.05M

Total Debt

$54.37M

Coherus Oncology Performance Analysis

Coherus Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 211,042,000	-35.4%
2023	2023-12-31	USD 257,244,000	21.9%
2024	2024-12-31	USD 26,389,000	-89.7%
2025	2025-12-31	USD 42,172,000	59.8%

Coherus Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	34.9%
Q3	2025-09-30	12.8%
Q4	2025-12-31	10.2%
Q1	2026-03-31	-3.4%

Coherus Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.76	-1.2%
2023	2023-12-31	USD -2.53	-32.8%
2024	2024-12-31	USD -1.29	-48.8%
2025	2025-12-31	USD -1.45	12.5%

Coherus Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	20.4%
Q3	2025-09-30	23.1%
Q4	2025-12-31	-3.3%
Q1	2026-03-31	9.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$12.31M

+62.0%

Gross Profit

$7.62M

+95.3%

Gross Margin

61.86%

N/A

Market Cap

$220.58M

N/A

Market Cap/Employee

$1.50M

N/A

Employees

147

N/A

Net Income

-$37.94M

+32.9%

EBITDA

-$33.87M

+23.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$167.05M

+102.7%

Total Debt

$54.37M

-79.9%

Accounts Receivable

$22.51M

-63.9%

Inventory

$4.83M

+37.2%

Long Term Debt

$52.47M

-80.4%

Short Term Debt

$1.90M

+10.2%

Return on Assets

-57.01%

N/A

Return on Invested Capital

-1.27%

N/A

Free Cash Flow

-$57.89M

-124.1%

Operating Cash Flow

-$57.89M

-124.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$17.76-2.15%

OABIOmniAb, Inc.

OABIOmniAb, Inc.$2.04-3.32%

CDXSCodexis, Inc.

CDXSCodexis, Inc.$1.99-3.40%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.61-1.76%

TARAProtara Therapeutics, Inc.

TARAProtara Therapeutics, Inc.$4.04-0.98%

CCCCC4 Therapeutics, Inc.

CCCCC4 Therapeutics, Inc.$3.65-2.41%

IMDXInsight Molecular Diagnostics Inc.

IMDXInsight Molecular Diagnostics Inc.$4.96-0.60%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.76-0.29%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.56-0.08%

SMCISuper Micro Computer

SMCISuper Micro Computer$31.20+0.02%

ONDSOndas

ONDSOndas$7.93-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$66.30-0.06%

HBANHuntington Bancshares

HBANHuntington Bancshares$17.40-0.05%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$10.96+0.16%

Questions About CHRS

What is the current price of Coherus Oncology?

Coherus Oncology is trading at $1.43 per share.

What is the 52-week range for Coherus Oncology?

Over the past 52 weeks, Coherus Oncology has traded between $0.81 and $2.62.

How much debt does Coherus Oncology have?

As of the most recent reporting period, Coherus Oncology reported total debt of $54.37M.

How much cash does Coherus Oncology have on hand?

Coherus Oncology reported $115.24M in cash and cash equivalents in its most recent financial results.

What is Coherus Oncology’s dividend yield?

Coherus Oncology does not currently have a dividend yield.

Coherus Oncology(NASDAQ) CHRS

Coherus Oncology Financials at a Glance

CHRS News

Coherus (CHRS) Q2 Revenue Jumps 10%

Why Coherus Biosciences Stock Tumbled on Thursday

Why Coherus BioSciences Stock Jumped Today

Why Coherus BioSciences Stock Is Sinking Today

Why Coherus Biosciences Popped Today

Why Coherus BioSciences Stock Jumped Today

Why Coherus BioSciences Was Plummeting This Week

Why Coherus Biosciences Stock Dropped Today

CHRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Coherus Oncology

A Targeted Cancer Portfolio

New Partners and Strategic Moves

What Sets Coherus Apart

Tracking the Financial Progress

Bottom Line

CHRS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Coherus Oncology Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CHRS

What is the current price of Coherus Oncology?

What is the 52-week range for Coherus Oncology?

How much debt does Coherus Oncology have?

How much cash does Coherus Oncology have on hand?

What is Coherus Oncology’s dividend yield?

Premium Investing Services